Currently, clinical trials evaluating STING agonists (either as monotherapy or in combination with ICIs, radiotherapy or chemotherapy) for the treatment of solid tumours such as BCa, RCC and PCa have been extensively initiated (Table 1). The gene discussed is STING1; the disease is posterior cortical atrophy.